CCM
TARA icon

Catalio Capital Management’s Protara Therapeutics TARA Stock Holding History

Catalio Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Sell
520,148
-59,876
-10% -$285K 0.37% 34
2026
Q1 		$3.02M Sell
580,024
-866,230
-60% -$5.13M 0.63% 31
2025
Q4 		$7.71M Sell
1,446,254
-54,539
-4% -$303K 1.36% 29
2025
Q3 		$6.53M Sell
1,500,793
-125,577
-8% -$407K 1.21% 26
2025
Q2 		$4.93M Buy
1,626,370
+537,679
+49% +$1.85M 1.03% 24
2025
Q1 		$4.64M Hold
1,088,691
– – 1.13% 20
2024
Q4 		$5.75M Buy
+1,088,691
New +$3.52M 1.26% 24

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Catalio Capital Management's TARA Position: Q2 2026 in Review

Catalio Capital Management reduced its Protara Therapeutics (TARA) stake by 10% in Q2 2026, selling an estimated $285K and leaving 520,148 shares worth $1.99M. The position accounts for 0.37% of the portfolio, ranked #34.

Catalio Capital Management first reported a position in TARA in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.71M in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Catalio Capital Management held 520,148 shares of Protara Therapeutics worth $1.99M as of Q2 2026.
  • Catalio Capital Management sold 59,876 Protara Therapeutics shares in Q2 2026, an estimated $285K.
  • Protara Therapeutics made up 0.37% of Catalio Capital Management's portfolio in Q2 2026, its #34 holding.
  • Catalio Capital Management first reported a position in Protara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Catalio Capital Management's Protara Therapeutics position peaked at $7.71M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.